Camagüey, Jan 4. – PORVAC vaccines against classical swine fever (CSF) and GAVAC against the bacillus produced by Camaguey's Genetic Engineering and Biotechnology Center (CIGB) have strengthened their presence on the domestic market in 2018.
Over one million cattle across the country have benefited from the use of GAVAC, an antigen designed in this institution for the integrated control of ticks of the genus Rhipicephalus (boophilus) microplus, most commonly in Cuban paddles, confirmed by the Cuban News Agency Nemesio González Fernández, Interim Director of CIGB.
By the end of 2018, more than two million 600,000 doses of vaccine were marketed nationwide, a figure higher than last year, as part of a multi-sectoral strategy involving the Ministry of Agriculture, the Ministry of Agriculture and CIGB. Department of Animal Health and other entities.
In the case of PORVAC, whose large-scale production began at the center of Camagüey's biotechnology in the recent year, it already has a presence in the genetic and multiplication units of the pig industry in all provinces, being provided in a pyramid scheme.
By 2019, the 1.2 million doses of this subunit vaccine obtained from the combination of viruses and porcine proteins and expected to be more effective and safer than those of the attenuated virus on the market, noted González Fernández.
In 2018, more than 954,600 doses of PORVAC were marketed, eradicating the vertical transmission of the virus from mothers to descendants through placenta, which gives PORVAC a high added value, more if he says PPP is one of diseases that cause more damage to the pig industry worldwide.
In 2019 CIGB Camaguey intends to continue to strengthen the presence of its products on the national market and to attract investment to improve its installed technological capability. (ACN) (Photo: Archive)